Skip to main content

ANTIBODY DERIVATIVES AS MOLECULAR AGENTS FOR NEOPLASTIC TARGETING

Objective

The selective delivery of bioactive agents (cytotoxics, radionuclides, cytokines) at the tumor site, while sparing normal tissues, represents one of the most promising avenues for the development of anticancer therapies with unprecedented efficacy and tolerability. Monoclonal antibodies represent the preferred vehicle for the targeted delivery of bioactive agents to cancer sites, as they can display a preferential accumulation in primary and metastatic tumor lesions already few hours after intravenous administration. Certain monoclonal antibody derivatives can remain on the neoplastic mass for several days, thus enabling the slow release of potent cytotoxics or the continuous action of bioactive agents such as cytokines or therapeutic radionuclides. The ADAMANT Project aims at the generation of anticancer agents of superior quality, which rely on the antibody-based delivery of cytotoxics, radionuclides or immunostimulatory cytokines to either vascular tumor antigens or to tumor cell membranes. While clinically-validated antibodies will allow the rapid development of therapeutic strategies based on novel antibody derivatives, innovative perfusion-based chemical proteomic technologies will facilitate the discovery of accessible and abundant tumor-associated antigens, ideally suited for the targeted delivery of bioactive agents to cancer sites. Imaging methodologies will guide us in the selection of antigens, antibodies and therapeutic agents with optimal pharmacokinetis and pharmacodynamics. Finally, therapy studies in tumor-bearing mice, featuring the use of antibody-derivatives in combination with other anti-cancer drugs (cytotoxic, biological, vascular disrupting agents) will provide insights about how to best translate the results of the ADAMANT Project to clinical development. The Project will be truly successful if at least one antibody-based tumor targeting agent enters full-blown industrial development programs by the end of the ADAMANT Project.

Field of science

  • /medical and health sciences/clinical medicine/oncology/cancer

Call for proposal

FP7-HEALTH-2007-A
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
Address
Via Mario Negri 2
20156 Milano
Italy
Activity type
Research Organisations
EU contribution
€ 606 000
Administrative Contact
Maria Rosa Bani (Dr.)

Participants (8)

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
Switzerland
EU contribution
€ 360 000
Address
Raemistrasse 101
8092 Zuerich
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Dario Neri (Prof.)
FRIEDRICH-SCHILLER-UNIVERSITAT JENA
Germany
EU contribution
€ 360 000
Address
Furstengraben 1
07743 Jena
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Alexander Berndt (Dr.)
KEMOTECH SRL
Italy
EU contribution
€ 156 000
Address
Edificio 3 Localita Piscinamanna
09010 Pula
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Matteo Zanda (Dr.)
PHILOCHEM AG
Switzerland
EU contribution
€ 240 000
Address
Libernstrasse 3
8112 Otelfingen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Eveline Trachsel (Dr.)
FONDAZIONE SENDO
Italy
EU contribution
€ 198 000
Address
Corso Venezia 18
20124 Milano
Activity type
Research Organisations
Administrative Contact
Silvia Marsoni (Dr.)
University College London
United Kingdom
EU contribution
€ 360 000
Address
Gower Street
WC1E 6BT London
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Rosamund Barbara Pedley (Dr.)
UNIVERSITE DE LIEGE
Belgium
EU contribution
€ 360 000
Address
Place Du 20 Aout 7
4000 Liege
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Isabelle Halleux (Dr.)
VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG
Netherlands
EU contribution
€ 360 000
Address
De Boelelaan 1105
1081 HV Amsterdam
Activity type
Higher or Secondary Education Establishments
Administrative Contact
D. Bonink (Dr.)